Hepatocyte-specific Mas Activation Enhances Lipophagy and Fatty Acid Oxidation to Protect Against Acetaminophen-Induced Hepatotoxicity in Mice
Shuai Chen,Zhi Lu,Haoyu Jia,Bo Yang,Chun Liu,Yuxin Yang,Shuo Zhang,Zhijing Wang,Liu Yang,Shanshan Li,Jing Li,Changqing Yang
DOI: https://doi.org/10.1016/j.jhep.2022.10.028
IF: 25.7
2023-01-01
Journal of Hepatology
Abstract:Background & Aims: Acetaminophen (APAP) is the most common cause of drug-induced liver injury (DILI); however, treatment options are limited. Mas is a G protein-coupled receptor whose role in APAP-induced hepatotoxicity has not yet been examined. Methods: Intrahepatic Mas expression was determined in both human and mouse DILI models. Mas1(-/-), AlbcreMas1(f/f), Ppara(-/-), Mas1(-/-)Ppara(-/-) and wild-type mice were challenged with APAP for the in vivo analyses of Mas-AKT-FOXO1 axis-dependent lipophagy and fatty acid oxidation (FAO), using pharmacological compounds and genetic tools. Liver samples were collected for RNA-sequencing, proteomics, metabolomics, lipidomics, and metabolic flux analysis. Live-imaging of liver and histological, biochemical, and molecular studies were performed to evaluate APAP-induced hepatotoxicity in mice. Primary hepatocytes and hepatic cell lines were exposed to APAP for in vitro analysis. Results: Intrahepatic Mas expression was significantly upregulated in human and mouse DILI models. Mice with systemic, liver-specific, or hepatocyte-specific Mas1 deficiency were vulnerable to APAP-induced hepatotoxicity. They exhibited substantially impaired lipophagy and downstream FAO, which was accompanied by the activation of AKT and suppression of FOXO1. In addition, the prophylactic activation of Mas conferred strong protection against APAP challenge in mice, with remarkably enhanced lipophagy and FAO dependent on the AKT-FOXO1 axis. Moreover, the protective effects of AVE0991 were substantially diminished by the inhibition of either lipophagy or FAO. Conclusions: The activation of Mas on hepatocytes enhanced AKT-FOXO1-dependent lipophagy and downstream FAO, protecting mice from APAP-induced hepatotoxicity and indicating that hepatocyte-specific Mas might be a novel therapeutic target for DILI. (c) 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.